Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 2
2011 1
2012 2
2013 2
2014 3
2015 4
2016 1
2017 4
2018 3
2019 1
2020 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

24 results
Results by year
Filters applied: . Clear all
Page 1
TREM2 Modulation Remodels the Tumor Myeloid Landscape Enhancing Anti-PD-1 Immunotherapy.
Molgora M, Esaulova E, Vermi W, Hou J, Chen Y, Luo J, Brioschi S, Bugatti M, Omodei AS, Ricci B, Fronick C, Panda SK, Takeuchi Y, Gubin MM, Faccio R, Cella M, Gilfillan S, Unanue ER, Artyomov MN, Schreiber RD, Colonna M. Molgora M, et al. Among authors: gubin mm. Cell. 2020 Aug 20;182(4):886-900.e17. doi: 10.1016/j.cell.2020.07.013. Epub 2020 Aug 11. Cell. 2020. PMID: 32783918 Free PMC article.
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression.
Chang CH, Qiu J, O'Sullivan D, Buck MD, Noguchi T, Curtis JD, Chen Q, Gindin M, Gubin MM, van der Windt GJ, Tonc E, Schreiber RD, Pearce EJ, Pearce EL. Chang CH, et al. Among authors: gubin mm. Cell. 2015 Sep 10;162(6):1229-41. doi: 10.1016/j.cell.2015.08.016. Epub 2015 Aug 27. Cell. 2015. PMID: 26321679 Free PMC article.
High-Dimensional Analysis Delineates Myeloid and Lymphoid Compartment Remodeling during Successful Immune-Checkpoint Cancer Therapy.
Gubin MM, Esaulova E, Ward JP, Malkova ON, Runci D, Wong P, Noguchi T, Arthur CD, Meng W, Alspach E, Medrano RFV, Fronick C, Fehlings M, Newell EW, Fulton RS, Sheehan KCF, Oh ST, Schreiber RD, Artyomov MN. Gubin MM, et al. Cell. 2018 Nov 1;175(4):1014-1030.e19. doi: 10.1016/j.cell.2018.09.030. Epub 2018 Oct 18. Cell. 2018. PMID: 30343900 Free PMC article.
MHC-II neoantigens shape tumour immunity and response to immunotherapy.
Alspach E, Lussier DM, Miceli AP, Kizhvatov I, DuPage M, Luoma AM, Meng W, Lichti CF, Esaulova E, Vomund AN, Runci D, Ward JP, Gubin MM, Medrano RFV, Arthur CD, White JM, Sheehan KCF, Chen A, Wucherpfennig KW, Jacks T, Unanue ER, Artyomov MN, Schreiber RD. Alspach E, et al. Among authors: gubin mm. Nature. 2019 Oct;574(7780):696-701. doi: 10.1038/s41586-019-1671-8. Epub 2019 Oct 23. Nature. 2019. PMID: 31645760 Free PMC article.
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.
Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD, Krebber WJ, Mulder GE, Toebes M, Vesely MD, Lam SS, Korman AJ, Allison JP, Freeman GJ, Sharpe AH, Pearce EL, Schumacher TN, Aebersold R, Rammensee HG, Melief CJ, Mardis ER, Gillanders WE, Artyomov MN, Schreiber RD. Gubin MM, et al. Nature. 2014 Nov 27;515(7528):577-81. doi: 10.1038/nature13988. Nature. 2014. PMID: 25428507 Free PMC article.
CANCER. The odds of immunotherapy success.
Gubin MM, Schreiber RD. Gubin MM, et al. Science. 2015 Oct 9;350(6257):158-9. doi: 10.1126/science.aad4140. Science. 2015. PMID: 26450194 No abstract available.
The RNA-Binding Protein HuR Posttranscriptionally Regulates IL-2 Homeostasis and CD4+ Th2 Differentiation.
Techasintana P, Ellis JS, Glascock J, Gubin MM, Ridenhour SE, Magee JD, Hart ML, Yao P, Zhou H, Whitney MS, Franklin CL, Martindale JL, Gorospe M, Davis WJ, Fox PL, Li X, Atasoy U. Techasintana P, et al. Among authors: gubin mm. Immunohorizons. 2017 Aug 1;1(6):109-123. doi: 10.4049/immunohorizons.1700017. Immunohorizons. 2017. PMID: 30035254 Free PMC article.
24 results